GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a medical device company advancing stroke treatment through next-generation catheter technology, today announced publication of the final results of the MARRS pivotal study in the Journal of Neurointerventional Surgery. The trial met its primary endpoint, with successful reperfusion mTICI 2b-3 achieved in 89% of patients without rescue therapy – exceeding the prespecified performance goal. The study also demonstrated a 75% first-pass effect mTICI 2c-3
See the full post here as oringinally posted on this site.
